These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 9362523)

  • 1. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
    Chu RS; Targoni OS; Krieg AM; Lehmann PV; Harding CV
    J Exp Med; 1997 Nov; 186(10):1623-31. PubMed ID: 9362523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
    J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.
    Ioannou XP; Gomis SM; Karvonen B; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S
    Vaccine; 2002 Nov; 21(1-2):127-37. PubMed ID: 12443671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.
    Fonseca DM; Silva CL; Paula MO; Soares EG; Marchal G; Horn C; Bonato VL
    Immunology; 2007 Aug; 121(4):508-17. PubMed ID: 17433075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
    Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
    J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides.
    Wang Y; Krieg AM
    Vaccine; 2004 Jun; 22(20):2641-50. PubMed ID: 15193390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligodeoxynucleotides containing CpG motifs induce low levels of TNF-alpha in human B lymphocytes: possible adjuvants for Th1 responses.
    Bohle B; Orel L; Kraft D; Ebner C
    J Immunol; 2001 Mar; 166(6):3743-8. PubMed ID: 11238615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice.
    Maletto B; Rópolo A; Morón V; Pistoresi-Palencia MC
    J Leukoc Biol; 2002 Sep; 72(3):447-54. PubMed ID: 12223511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.
    Diwan M; Tafaghodi M; Samuel J
    J Control Release; 2002 Dec; 85(1-3):247-62. PubMed ID: 12480329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    Roda JM; Parihar R; Carson WE
    J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism.
    Chiaramonte MG; Hesse M; Cheever AW; Wynn TA
    J Immunol; 2000 Jan; 164(2):973-85. PubMed ID: 10623847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.
    McCluskie MJ; Weeratna RD; Davis HL
    Vaccine; 2001 Mar; 19(17-19):2657-60. PubMed ID: 11257405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
    Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
    J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T helper 2 immunity to hepatitis B surface antigen primed by gene-gun-mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif-containing oligodeoxynucleotides.
    Zhou X; Zheng L; Liu L; Xiang L; Yuan Z
    Scand J Immunol; 2003 Sep; 58(3):350-7. PubMed ID: 12950682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Clin Chem Lab Med; 1999 Mar; 37(3):199-204. PubMed ID: 10353461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
    Weeratna RD; Brazolot Millan CL; McCluskie MJ; Davis HL
    FEMS Immunol Med Microbiol; 2001 Dec; 32(1):65-71. PubMed ID: 11750224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation of Japanese encephalitis vaccine through CpG oligodeoxynucleotides in mice.
    Sidhapuriwala JN; Sivalingam SP; Lu J; Moochhala SM
    Scand J Immunol; 2006 Oct; 64(4):370-5. PubMed ID: 16970676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
    Liu Y; Luo X; Yang C; Yu S; Xu H
    Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.
    Vasilakos JP; Smith RM; Gibson SJ; Lindh JM; Pederson LK; Reiter MJ; Smith MH; Tomai MA
    Cell Immunol; 2000 Aug; 204(1):64-74. PubMed ID: 11006019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.